

Supplementary material

Polok K, Iwaniec T, Stachura T, et al. Temporal changes of hemostatic activity in patients hospitalized for COVID-19: a prospective observational study. Pol Arch Intern Med. 2023; 133: 16446. doi:10.20452/pamw.16446

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

Supplementary Table 1. Comparison of hemostatic markers between the admission and 28-day follow-up in patients requiring no oxygen.

	Admission	28-day follow-up	p-value ^a
NO OXYGEN (n=30)			
Fibrinogen (g/L)	3.95 [3.50; 4.50]	3.20 (2.62; 3.38)	<0.001
Factor VIII (%)	137.00 [99.00; 167.28]	116.40 (89.20; 151.48)	0.008
TAT (ug/l)	6.98 [4.45; 12.89]	4.56 (3.42; 5.86)	<0.001
CLT (min)	104.00 [96.00; 125.00]	99.00 (91.25; 104.50)	<0.001
D-dimer (ng/ml)	836.00 [552.75; 1534.75]	624.00 (319.75; 1032.25)	0.001
Alpha2-antiplasmin (%)	107.60 [101.33; 111.20]	104.35 (100.67; 109.42)	<0.001
Plasminogen (%)	119.25 [106.73; 135.02]	120.00 (109.40; 133.48)	0.85
t-PA:Ag (ng/ml)	9.55 [6.14; 12.67]	6.83 (5.42; 9.16)	<0.001
PAI-1:Ag (ng/ml)	29.21 [22.74; 39.80]	22.80 (15.20; 30.50)	<0.001
PAP (ng/ml)	1393.28 [1180.13; 1939.62]	732.18 (593.68; 933.94)	<0.001
vWF:Ag (%)	238.90 [179.37; 284.55]	142.60 (112.45; 195.08)	<0.001
ADAMTS-13 (IU/ml)	0.83 [0.75; 0.95]	0.88 (0.82; 0.94)	0.051
vWF:Ag/ADAMTS ratio	3.12 [2.22; 3.61]	1.60 (1.33; 2.14)	<0.001
LOW-FLOW OXYGEN THERAPY (n=91)			
Fibrinogen (g/L)	4.40 (3.80; 5.10)	3.20 (2.80; 3.60)	<0.001
Factor VIII (%)	142.10 (108.75; 182.15)	120.80 (87.65; 162.45)	0.09
TAT (ug/l)	7.20 (5.35; 12.09)	4.48 (3.67; 6.42)	0.002
CLT (min)	110.00 (100.00; 125.75)	98.00 (86.00; 106.75)	0.008
D-dimer (ng/ml)	830.00 (581.00; 1449.00)	644.00 (405.50; 1084.00)	0.039
Alpha2-antiplasmin (%)	110.60 (105.05; 115.95)	104.20 (98.90; 108.35)	0.85
Plasminogen (%)	122.90 (110.55; 132.05)	119.40 (111.20; 129.95)	0.73
t-PA:Ag (ng/ml)	13.65 (9.31; 16.97)	8.09 (6.19; 9.33)	0.012
PAI-1:Ag (ng/ml)	33.85 (21.52; 43.37)	22.36 (14.41; 32.96)	0.024
PAP (ng/ml)	1548.86 (1352.55; 2000.11)	732.18 (596.15; 1074.32)	<0.001
vWF:Ag (%)	305.40 (243.65; 363.85)	174.30 (121.65; 228.45)	<0.001
ADAMTS-13 (IU/ml)	0.88 (0.84; 0.92)	0.89 (0.83; 0.93)	0.09
vWF:Ag/ADAMTS ratio	3.49 (2.90; 4.09)	1.98 (1.36; 2.73)	<0.001
ADVANCED RESPIRATORY SUPPORT (n=43)			
Fibrinogen (g/L)	5.00 (4.05; 5.65)	3.40 (2.90; 3.70)	<0.001
Factor VIII (%)	134.30 (112.65; 170.20)	131.40 (93.75; 163.30)	0.041
TAT (ug/l)	9.15 (7.22; 16.13)	4.83 (3.84; 7.68)	<0.001
CLT (min)	119.00 (104.00; 144.50)	103.00 (93.50; 119.00)	<0.001
D-dimer (ng/ml)	865.00 (617.00; 1438.00)	679.00 (396.00; 1026.50)	<0.001
Alpha2-antiplasmin (%)	112.30 (103.95; 115.95)	105.80 (101.10; 109.70)	0.002
Plasminogen (%)	127.10 (120.10; 135.90)	127.10 (118.60; 134.85)	0.67
t-PA:Ag (ng/ml)	13.90 (11.45; 17.95)	9.08 (6.31; 11.64)	<0.001
PAI-1:Ag (ng/ml)	38.13 (28.50; 43.03)	22.71 (14.45; 35.40)	<0.001
PAP (ng/ml)	1722.60 (1425.76; 2000.11)	754.86 (596.15; 1165.24)	<0.001
vWF:Ag (%)	333.50 (287.95; 388.15)	205.60 (168.85; 252.15)	<0.001
ADAMTS-13 (IU/ml)	0.85 (0.79; 0.90)	0.86 (0.81; 0.92)	0.11
vWF:Ag/ADAMTS ratio	4.05 (3.52; 4.65)	2.33 (1.95; 2.91)	<0.001

Footnote: CLT, clot lysis time; PAI-1, plasminogen activator inhibitor 1; PAP, plasmin-antiplasmin complexes; TAT, thrombin-antithrombin complexes; tPA:Ag, tissue plasminogen activator: antigen; vWF:Ag, von Willebrand factor: antigen.

^a p-value for Wilcoxon test

Supplementary Table 2. Comparison of APL antibodies prevalence between the admission and 28-day follow-up in patients with available follow-up

Factor	Admission	28-day follow-up	p-value ^a
Positive aCL IgG antibodies	14 (8.5)	58 (35.4)	<0.001
Positive aCL IgM antibodies	109 (66.5)	125 (76.2)	0.034
Positive aCL antibodies	111 (67.7)	133 (81.1)	0.004
Positive anti-B ₂ GP1 IgG antibodies	6 (3.7)	7 (4.3)	1
Positive anti-B ₂ GP1 IgM antibodies	7 (4.3)	8 (4.9)	1
Positive anti-B ₂ GP1 antibodies	11 (6.7)	14 (8.5)	0.45
Positive aPS/PT IgG antibodies	6 (3.7)	6 (3.7)	1
Positive aPS/PT IgM antibodies	25 (15.2)	25 (15.2)	1
Positive aPS/PT antibodies	29 (17.7)	28 (17.1)	1
Number of positive antibodies			
0	48 (29.3)	31 (18.9)	
1	87 (53.0)	94 (57.3)	
2	23 (14.0)	36 (22.0)	
3	6 (3.7)	3 (1.8)	

Footnote: anti-B₂GP, anti-beta₂glycoprotein 1; 1 aCL, anticardiolipin; aPS/PT, anti phosphatidylserine/prothrombin.

^a p-value for McNemar test

Supplementary Table 3. Comparison of APL prevalence between the groups

Factor	Overall (n=245)	Advanced respiratory support (n=77)	Low-flow oxygen therapy (n=127)	No supplemental oxygen (n=41)	p-value ^a
Admission					
Positive aCL IgG antibodies	27 (11.0)	7 (9.1)	13 (10.2)	7 (17.1)	0.39
Positive aCL IgM antibodies	157 (64.1)	47 (61.0)	85 (66.9)	25 (61.0)	0.63
Positive aCL antibodies	163 (66.5)	49 (63.6)	87 (68.5)	27 (65.9)	0.77
Positive anti-B ₂ GP1 IgG antibodies	7 (2.9)	3 (3.9)	3 (2.4)	1 (2.4)	0.80
Positive anti-B ₂ GP1 IgM antibodies	10 (4.1)	2 (2.6)	7 (5.5)	1 (2.4)	0.50
Positive anti-B ₂ GP1 antibodies	15 (6.1)	5 (6.5)	9 (7.1)	1 (2.4)	0.55
Positive aPS/PT IgG antibodies	7 (2.9)	1 (1.3)	5 (3.9)	1 (2.4)	0.54
Positive aPS/PT IgM antibodies	39 (15.9)	13 (16.9)	21 (16.5)	5 (12.2)	0.77
Positive aPS/PT antibodies	43 (17.6)	13 (16.9)	24 (18.9)	6 (14.6)	0.81
Number of positive antibodies					0.93
0	75 (30.6)	26 (33.8)	36 (28.3)	13 (31.7)	
1	126 (51.4)	37 (48.1)	66 (52.0)	23 (56.1)	
2	37 (15.1)	12 (15.6)	21 (16.5)	4 (9.8)	
3	7 (2.9)	2 (2.6)	4 (3.1)	1 (2.4)	
28-day follow-up					
Positive aCL IgG antibodies	58 (35.4)	24 (55.8)	29 (31.9)	5 (16.7)	0.002
Positive aCL IgM antibodies	125 (76.2)	34 (79.1)	76 (83.5)	15 (50.0)	0.001
Positive aCL antibodies	133 (81.1)	38 (88.4)	78 (85.7)	17 (56.7)	0.001
Positive anti-B ₂ GP1 IgG antibodies	7 (4.3)	3 (7.0)	4 (4.4)	0 (0.0)	0.35
Positive anti-B ₂ GP1 IgM antibodies	8 (4.9)	0 (0.0)	7 (7.7)	1 (3.3)	0.14
Positive anti-B ₂ GP1 antibodies	14 (8.5)	3 (7.0)	10 (11.0)	1 (3.3)	0.39
Positive aPS/PT IgG antibodies	6 (3.7)	1 (2.3)	5 (5.5)	0 (0.0)	0.33
Positive aPS/PT IgM antibodies	25 (15.2)	7 (16.3)	16 (17.6)	2 (6.7)	0.35
Positive aPS/PT antibodies	28 (17.1)	7 (16.3)	19 (20.9)	2 (6.7)	0.20
Number of positive antibodies					0.001

0	31 (18.9)	5 (11.6)	13 (14.3)	13 (43.3)	
1	94 (57.3)	30 (69.8)	50 (54.9)	14 (46.7)	
2	36 (22.0)	6 (14.0)	27 (29.7)	3 (10.0)	
3	3 (1.8)	2 (4.7)	1 (1.1)	0 (0.0)	

Footnote: anti-B₂GP, anti-beta₂glycoprotein 1; 1 aCL, anticardiolipin; aPS/PT, anti phosphatidylserine/prothrombin.

^a p-value for chi-square test